TNBC, TRIPLE NEGATIVE BREAST CANCER

This early-phase study tests a new immunotherapy drug (QL1706) combined with short cycles of chemotherapy for people with early-stage triple-negative breast cancer (TNBC). TNBC is an aggressive cancer that lacks common targets, making it harder to treat. The trial will enroll 30 …

This program offers investigational leronlimab to adults with advanced or metastatic triple-negative breast cancer who have run out of standard treatment options. Participants must have confirmed HR-/HER2- cancer and have progressed on prior therapy. The goal is to provide potent…

This study tests a new combination of drugs (alpelisib, L-NMMA, and chemotherapy) in people with a rare and aggressive type of breast cancer called metaplastic breast cancer that has spread or cannot be removed by surgery. The goal is to see if the combination is safe and can shr…

This early-phase trial tests whether adding dupilumab (an allergy drug) to standard chemotherapy and immunotherapy is safe for people with locally advanced triple-negative breast cancer. About 15 participants will receive the combination before surgery. The main goal is to check …

This study tests whether adding a drug that blocks a certain immune cell (CSF-1R inhibitor) and radiation to standard immunotherapy (pembrolizumab) can improve outcomes for people with high-risk triple-negative breast cancer. About 35 participants will receive the combination bef…

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive breast cancer. About 34 participants will …

This study tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, and colorectal cancers. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants receive the drug every 3 weeks and are closely monitored…

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This early-phase study tests a new drug called 177Lu-RAD204, which is a radioactive antibody that seeks out and attaches to a protein (PD-L1) on cancer cells. The goal is to see if it is safe and tolerable for people with advanced solid tumors like lung, breast, or skin cancer th…

This study tests whether an MRI scan can identify triple-negative breast cancer patients who respond well to initial chemotherapy and can safely skip the second, more toxic part of treatment. About 54 participants will receive four cycles of chemo plus immunotherapy, then get an …

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, lung, or ovarian cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors, either alone or combined with ot…

This study tests whether adding two targeted drugs (sintilimab and bevacizumab) to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 37 women with stage II-III disease. The main goal is to see how many patients have no cancer left in t…

This study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery. …

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 35 women. Participants will receive the drug combination, then have surgery, and be followed for side effects and c…

This early-phase study tests a new treatment called 177LuBetaBart for people with advanced solid tumors that have stopped responding to standard therapies. The treatment combines a targeting antibody with a radioactive particle to deliver radiation directly to cancer cells. The s…

This study tests a new approach for people with triple-negative breast cancer whose tumors did not shrink after initial chemotherapy. Participants receive a short course of high-precision radiation to the breast tumor, followed by immunotherapy (toripalimab) combined with more ch…

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage triple-negative breast cancer (TNBC). TNBC is a hard-to-treat type of breast cancer with fewer treatment options. The trial will e…

This phase 2 trial tests whether injecting the drug INT230-6 into the tumor before standard chemotherapy and immunotherapy can increase the chance of eliminating all cancer in the breast and lymph nodes before surgery. About 61 people with early triple-negative breast cancer will…

This is a first-in-human study to test the safety and find the right dose of a new drug called BAL0891. It will be given alone and in combination with other cancer drugs to 260 adults with advanced solid tumors (like certain breast and stomach cancers) or a type of leukemia that …

This study tests a new, non-invasive imaging device that uses light to monitor how breast tumors respond to chemotherapy. Researchers want to see if it can accurately predict when the cancer has been completely eliminated (called a complete pathological response). The study invol…

This study tests if a special mammogram with contrast dye can predict whether breast cancer has been completely eliminated by chemotherapy, just as well as an MRI does. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms during or after chemo, befo…

This study involves 300 Chinese patients with metastatic triple-negative breast cancer that has worsened after first treatment. It compares how patients feel (quality of life and symptoms) when taking sacituzumab govitecan versus standard chemotherapy chosen by their doctor. The …

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. Finding this DNA, called minimal residual disease, may help predict if the cancer will come back. The study will follow 900 people with different types…

This study aims to match breast cancer patients with the most effective experimental drugs based on their tumor's unique features. Up to 5,000 participants will receive standard chemotherapy plus an experimental agent before surgery. Researchers will use MRI scans, tissue, and bl…

This study is for women with triple-negative breast cancer, either early-stage or advanced, who are receiving immunotherapy. Researchers want to see if changes in a blood marker called CRP can help predict how well the treatment works. The goal is to find a simple way to guide tr…

This study collects live tumor tissue from 2,000 people with various cancers to understand why some respond to immunotherapy and others don't. Participants give a biopsy as part of their normal care, and researchers analyze the samples in the lab. The goal is to develop better wa…